Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 8, 2025

Critical Minerals Sector Becoming More Critical as Global Antimony Mineral Market is Growing at Rapid Pace

View original at globenewswire.com
Critical Minerals Sector Becoming More Critical as Global Antimony Mineral Market is Growing at Rapid Pace MarketNewsUpdatesNews Commentary NEW YORK, Dec…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • With the first DOE Loan drawdown received, project certainty and stability have been significantly enhanced

    80% confidence

  • This agreement represents another important step in developing a fully integrated, American-controlled supply chain for antimony

    80% confidence

  • China still controls approximately 60% of global antimony production

    80% confidence

  • Approximately 700 workers are now on-site at Thacker Pass with over 80% of detailed engineering complete

    80% confidence

  • The global antimony mineral market is experiencing significant growth, fueled by rising demand from flame retardant applications

    80% confidence

  • This work will help validate the processing characteristics of Nevada-sourced material and advance U.S. refining capability for antimony

    80% confidence

  • Antimonial lead alloys constitute nearly 20% of global antimony consumption in battery applications

    80% confidence

  • Asia-Pacific dominates the global antimony mineral market, accounting for over 60% of global demand as of 2024

    80% confidence

  • Antimony trioxide accounts for approximately 65% of total antimony consumption globally

    80% confidence

  • The newest team members bring several decades of expertise that will help Perpetua bring its gold and antimony project in central Idaho to life

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com